• Langley Road, Brighton, MA
  • 416-402-8274

NIH Licensing Opportunity: A Novel Personalized Cell Therapy for Age-related Macular Degeneration


Signature Square OMSIH logo

NIH Licensing Opportunity: A Novel Personalized Cell Therapy for Age-related Macular Degeneration


register here  LIVE EVENT ONLY.

One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.

This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH.

This is also your opportunity to participate in our proprietary Signature Square process, where end-users can evaluate the technology, ask questions and provide feedback directly to the scientist.

A Novel Personalized Cell Therapy for Age-related Macular Degeneration

This novel technology acts as a potential cure for the millions of people worldwide suffering from Age-related Macular Degeneration (AMD). More than 30 million individuals suffer worldwide, and approximately US$300 billion is spent per a year in economic costs for this severely debilitating disease.  


This ground-breaking technology is a personalized cell therapy using induced pluripotent stem cell-derived retinal pigment epithelium (RPE). Patient-derived iPS cells are induced to differentiate into RPE cells, which can then be transplanted back into the patients via cell therapy, leading to a potential treatment for AMD. 

Current applications of this science include:

  • Personalized cell therapy for retinal degenerative diseases
  • GMP-manufacturing process for the use of iPS cells in other clinical applications
  • Highly efficient protocol to generate RPE cells for high throughput drug screening
  • Novel animal model & a surgical procedure to test therapeutic interventions for retinal degeneration
  • Pig injury-induced retinal degeneration model to test drugs and cell therapy
  • Surgical tool to transplant constructs in the eye
  • Minimally invasive surgical procedure for accessing the sub-retinal space

This science is ready for licensing to interested parties for scale-up production, so it can be made available to researchers and surgeons.  

Several aspects of this technology are ready for licensing or a CRADA. And, the whole technology is ready for partnering for commercial scale development. The associated scientists are also planning to perform a Phase I clinical trial with the cell therapy product, and hope to seek industry partners for subsequent phases, and for commercializing this product. 


The Signature Square process is part of our Consortium infrastructure. Current member companies in the Technology Evaluation Consortium and SafeTEC include organizations like Pfizer, AbbVie, Amgen and Allergan, along with many others, including scientists, clinicians and investors in organizations around the world who help to evaluate this technology. 

This is your opportunity to ask questions and provide feedback directly to the scientist by taking part in this Signature Square program. 


Earl Stadtman Tenure-Track Investigator
National Eye Institute
Dawn Van Dam
President & CEO
One Million Solutions in Health™


Note: This is a live event only. No recording will be available, except to members of the Technology Evaluation Consortium OR SafeTEC members. Contact us for membership information.